EAM Investors LLC Has $4.75 Million Holdings in Arrowhead Pharmaceuticals Inc (ARWR)
EAM Investors LLC grew its holdings in shares of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) by 192.5% in the third quarter, according to its most recent filing with the SEC. The firm owned 247,549 shares of the biotechnology company’s stock after acquiring an additional 162,916 shares during the quarter. Arrowhead Pharmaceuticals comprises approximately 0.7% of EAM Investors LLC’s holdings, making the stock its 18th largest position. EAM Investors LLC owned approximately 0.28% of Arrowhead Pharmaceuticals worth $4,746,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in ARWR. Northern Trust Corp boosted its stake in Arrowhead Pharmaceuticals by 12.7% during the first quarter. Northern Trust Corp now owns 221,517 shares of the biotechnology company’s stock worth $1,597,000 after acquiring an additional 24,932 shares in the last quarter. UBS Group AG boosted its stake in Arrowhead Pharmaceuticals by 798.0% during the first quarter. UBS Group AG now owns 202,765 shares of the biotechnology company’s stock worth $1,462,000 after acquiring an additional 180,186 shares in the last quarter. Amalgamated Bank bought a new stake in Arrowhead Pharmaceuticals during the second quarter worth about $181,000. Janney Montgomery Scott LLC boosted its stake in Arrowhead Pharmaceuticals by 28.9% during the second quarter. Janney Montgomery Scott LLC now owns 25,200 shares of the biotechnology company’s stock worth $343,000 after acquiring an additional 5,650 shares in the last quarter. Finally, CIBC Private Wealth Group LLC bought a new stake in Arrowhead Pharmaceuticals during the second quarter worth about $1,088,000. Institutional investors own 59.39% of the company’s stock.
ARWR has been the topic of several analyst reports. BidaskClub downgraded shares of Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, October 6th. Chardan Capital set a $25.00 target price on shares of Arrowhead Pharmaceuticals and gave the stock a “buy” rating in a research note on Sunday, October 14th. Jefferies Financial Group upped their target price on shares of Arrowhead Pharmaceuticals to $24.00 and gave the stock a “buy” rating in a research note on Friday, September 14th. Cantor Fitzgerald set a $18.00 target price on shares of Arrowhead Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, October 2nd. Finally, Piper Jaffray Companies reiterated an “overweight” rating and issued a $25.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Thursday, October 4th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $21.45.
Shares of NASDAQ ARWR opened at $13.39 on Friday. Arrowhead Pharmaceuticals Inc has a 52-week low of $3.01 and a 52-week high of $22.39. The company has a debt-to-equity ratio of 0.02, a quick ratio of 8.69 and a current ratio of 8.69.
COPYRIGHT VIOLATION NOTICE: “EAM Investors LLC Has $4.75 Million Holdings in Arrowhead Pharmaceuticals Inc (ARWR)” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.dailypolitical.com/2018/11/18/eam-investors-llc-has-4-75-million-holdings-in-arrowhead-pharmaceuticals-inc-arwr.html.
Arrowhead Pharmaceuticals Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its medicines include ARO-HBV, a Phase I/II subcutaneous ribonucleic acid interference(RNAi) therapy candidate that is used for the treatment of chronic hepatitis B viral infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.
Recommended Story: Cost of Debt
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.